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The retrotransposon Long Interspersed Element 1 (LINE-1 or L1) is a continuing source of germline and somatic mutagenesis
in mammals. Deregulated L1 activity is a hallmark of cancer, and L1 mutagenesis has been described in numerous human
malignancies. We previously employed retrotransposon capture sequencing (RC-seq) to analyze hepatocellular carcinoma
(HCC) samples from patients infected with hepatitis B or hepatitis C virus and identified L1 variants responsible for activating
oncogenic pathways. Here, we have applied RC-seq and whole-genome sequencing (WGS) to an Abcb4 (Mdr2)−/− mouse
model of hepatic carcinogenesis and demonstrated for the first time that L1 mobilization occurs in murine tumors. In 12
HCC nodules obtained from 10 animals, we validated four somatic L1 insertions by PCR and capillary sequencing, including
TF subfamily elements, and one GF subfamily example. One of the TF insertions carried a 3′ transduction, allowing us to
identify its donor L1 and to demonstrate that this full-length TF element retained retrotransposition capacity in cultured
cancer cells. Using RC-seq, we also identified eight tumor-specific L1 insertions from 25 HCC patients with a history of al-
cohol abuse. Finally, we used RC-seq and WGS to identify three tumor-specific L1 insertions among 10 intra-hepatic chol-
angiocarcinoma (ICC) patients, including one insertion traced to a donor L1 on Chromosome 22 known to be highly
active in other cancers. This study reveals L1 mobilization as a common feature of hepatocarcinogenesis in mammals, dem-
onstrating that the phenomenon is not restricted to human viral HCC etiologies and is encountered in murine liver tumors.
[Supplemental material is available for this article.]
Transposable element (TE) sequences make up at least half of the
human and mouse genomes (Lander et al. 2001; Waterston et al.
2002; de Koning et al. 2011).While most TE sequences are ancient
molecular fossils, a subset of evolutionarily young TEs retain the
ability to mobilize (Furano 2000). Both the human andmurine ge-
nomes are characterized by the activity of the retrotransposon
Long Interspersed Element-1 (LINE-1 or L1), which accounts for
19.9% and 17.5% of mouse and human genomic DNA, respective-
ly (Smit et al. 2013). Although the vast majority of L1 copies are no
longer mobile, 80–100 human L1s and 2000–3000 mouse L1s, per
individual, are full-length and retain retrotransposition potential
(Goodier et al. 2001; Brouha et al. 2003). Aside from L1, several ret-
rotransposon families are active in mice, including B1 and B2
SINEs, as well as LTR retrotransposons, such as IAP and ETn ele-
ments (Nellaker et al. 2012; Richardson et al. 2017). In humans,
there is one presently active L1 subfamily, L1-Ta, while three
mouse L1 subfamilies are known to be recently active: TF, GF,
and A. These mouse L1 subfamilies are primarily distinguished by
the sequence of the ∼200-bp repetitive units, or monomers,
comprising their 5′ UTR (DeBerardinis et al. 1998; Naas et al.
1998; Boissinot et al. 2000; Goodier et al. 2001). Full-length L1s
(∼6 kb in humans and ∼7 kb in mice) encode proteins required
for their own mobilization (i.e., retrotransposition) through re-
verse transcription of an RNA intermediate (Mathias et al. 1991;
Feng et al. 1996). L1 integration into the genome occurs by a pro-
cess termed target primed reverse transcription (TPRT) (Luan et al.
1993), which produces distinctive structural hallmarks, including12These authors contributed equally to this work.
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variable-length target site duplications (TSDs), a 3′ poly(A) tract,
frequent 5′ truncation of the L1 sequence, and insertion at a geno-
mic sequence motif resembling the consensus 5′-TT/AAAA-3′
(Singer et al. 1983; Scott et al. 1987; Feng et al. 1996; Jurka 1997).
Critically, characterization of both 5′ and 3′ termini of L1 inser-
tions to discern these structural hallmarks is essential to distin-
guish bona fide L1 insertions from other types of genomic
rearrangements involving L1 sequences (Richardson et al. 2014).
L1 is a potent endogenous insertional mutagen. Exonic L1
insertions are highly detrimental to gene function (Kazazian et
al. 1988; Miki et al. 1992; Scott et al. 2016), and intronic insertions
can compromise transcript integrity by introducing cryptic splice
sites and polyadenylation signals and can interfere with RNA
polymerase processivity, particularly when oriented in sense rela-
tive to the interrupted gene (Perepelitsa-Belancio and Deininger
2003; Han et al. 2004; Belancio et al. 2008). Furthermore, L1 inser-
tions are occasionally associated with deletions and rearrange-
ments to target site DNA, including extreme examples such as
chromosomal translocations (Gilbert et al. 2002, 2005). Indeed,
more than 100 cases of human genetic disease have been attribut-
ed to L1-mediated retrotransposition events (Hancks and Kaza-
zian 2016).
Due to its mutagenic potential, L1 expression and mobiliza-
tion is tightly regulated in most cell types and developmental
contexts, with CpG methylation of the L1 internal promoter rep-
resenting a key mechanism for control of L1 activity (Goodier and
Kazazian 2008). In themammalian germline and early embryo, L1
escapes repression to mobilize and create heritable insertions to
ensure its evolutionary success (Kano et al. 2009; Faulkner and
Garcia-Perez 2017; Richardson et al. 2017). More recently, somatic
L1 mobilization has been revealed as a characteristic of normal
neuronal cells in rodents and humans, and L1 dysregulation has
been associated with neurological diseases (Muotri et al. 2005,
2010; Baillie et al. 2011; Coufal et al. 2011; Evrony et al. 2012;
Upton et al. 2015; Erwin et al. 2016; Hazen et al. 2016).
Unchecked somatic L1 mobilization can lead to human dis-
ease in the context of oncogenesis and cancer progression. In
1992, Miki et al. identified an exonic L1 insertion into the APC
gene that very likely led to tumor initiation in a case of colorectal
cancer, providing the first direct evidence for L1 involvement in
oncogenesis (Miki et al. 1992). Since then, spurred by the advent
of high-throughput sequencing approaches for identifying endog-
enous somatic L1 insertions, L1mobilization events have been un-
covered in a plethora of tumor types, including lung, ovarian,
breast, colorectal, prostate, liver, pancreatic, gastric, endometrial,
and esophageal cancers (Iskow et al. 2010; Lee et al. 2012; Solyom
et al. 2012; Shukla et al. 2013; Helman et al. 2014; Tubio et al.
2014; Doucet-O’Hare et al. 2015, 2016; Ewing et al. 2015; Paterson
et al. 2015; Rodic et al. 2015; Scott et al. 2016). Although these stud-
ies have elucidated driver L1 mutations exonic to APC and PTEN,
most of the cataloged tumor-specific L1 insertions represent likely
passenger events (Helman et al. 2014; Scott et al. 2016). Evidence
for L1 mobilization in cancers is largely restricted to tumors of ep-
ithelial origin, with somatic L1 insertions conspicuously infre-
quent in brain and blood cancers (Iskow et al. 2010; Lee et al.
2012; Achanta et al. 2016; Carreira et al. 2016). Thus, some cancer
cell types may be intrinsically susceptible to L1 retrotransposition
(Carreira et al. 2014; Scott and Devine 2017).
Liver cancer is the sixth most prevalent type of cancer in the
world, with 782,000 new cases and 745,000 deaths in 2012 (Ferlay
et al. 2015), and is the second most common cause of death from
cancer worldwide (Petrick et al. 2016). In previous work (Shukla
et al. 2013), we investigated the frequency and impact of L1 mobi-
lization in hepatocellular carcinoma (HCC), which accounts for
∼80% of liver cancer cases (Petrick et al. 2016). Hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection are leading causes
of chronic liver disease and cirrhosis, which are, in turn, the
most important risk factors for the development of HCC (Balogh
et al. 2016). We applied retrotransposon-capture sequencing
(RC-seq) (Baillie et al. 2011; Shukla et al. 2013) to paired tumor/
nontumor samples from 19 donors positive for HBV or HCV and
uncovered and PCR-validated 12 tumor-specific somatic L1 inser-
tions. One intronic insertion resulted in the activation of the tran-
scriptional repressor and putative oncogene ST18 by disrupting a
binding site required for its own repression, demonstrating the ca-
pacity for intronic tumor-specific L1 insertions to contribute to
cancer progression. Notably, a recent study confirmed ST18 as a
liver oncogene, highlighting the value of mapping L1 insertions
in cancer genomes as an endogenous mutagenesis screen (Rava
et al. 2017).
In addition to HBV and HCV infection, alcoholism is also a
prominent risk factor for HCC (Balogh et al. 2016). However, the
involvement of somatic L1 mutagenesis in HCC in patients with
a history of alcoholismhas not been assessed, leaving the potential
restriction of L1 mobilization to viral HCC etiologies unresolved.
Indeed, increased accumulation of L1 DNA has been observed in
HIV-1 infected cultured cells, suggesting that in some cases viral
infection may render cells susceptible to increased L1 activity
(Jones et al. 2013). Other liver malignancies, such as intra-hepatic
cholangiocarcinoma (ICC), which is the second most common
type of liver cancer and arises from the epithelial cells lining the
bile ducts (Serafini and Radvinsky 2016), have not been investigat-
ed for tumor-specific L1 activity. Finally, it is unknown whether
tumor-specific L1 mutagenesis also occurs in rodents, leaving
open the question of whether L1 mobilization is peculiar to hu-
man epithelial cancers and, if not, whether its characteristics
vary among mammalian species, including animal models of
hepatocarcinogenesis.
Results
Liver tumor-specific L1 retrotransposition in Abcb4 (Mdr2)−/−mice
To investigate whether L1 mobilization is a feature of hepatocarci-
nogenesis in rodents, we employedmicewith homozygous disrup-
tion of the Abcb4 (also known asMdr2) gene. This Abcb4 (Mdr2)−/−
mouse (hereafterMdr2−/−) is an established model of human HCC
inwhich pathogenesis is attributed to the inability to secrete phos-
pholipid into bile, leading to hepatocellular damage, inflammato-
ry cholangitis, pre-neoplastic lesions and, ultimately, metastatic
liver cancer (Smit et al. 1993; Mauad et al. 1994). We isolated 12
HCC tumor nodules and matching tail tissue from 10 Mdr2−/−
mice at age 15 mo (Supplemental Table S1) and performed mouse
retrotransposon capture sequencing (mRC-seq) (Richardson et al.
2017) on tumor and tail genomic DNA and ∼45× whole-genome
sequencing (WGS) on each of five nodules from three animals
(Supplemental Table S1). Sequence analysis to identify putative
retroelement insertionswas performedusing the TEBreak bioinfor-
matic pipeline (https://github.com/adamewing/tebreak) and in-
tersected with known nonreference genome TE insertions found
in a wide array of mouse strains (Nellaker et al. 2012). Among
the 10 animals examined, we bioinformatically identified 748
polymorphic nonreference insertions, including 154 events com-
prising 42 SINE (11 B1 and 31 B2), three LTR (all ETn), and 109
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L1 (48A, 19GF, and 42TF) insertions not found in the parental FVB
or 129 mouse strains, or other sequenced strains (Supplemental
Table S2). Of the 154 insertions, 141 (91.6%) were found in multi-
ple animals, demonstrating that the vast majority of polymorphic
insertions we found were vertically inherited, rather than occur-
ring de novo in the animals analyzed here. Polymorphic insertions
were found within known cancer genes. For example, we identi-
fied an intact ETn retrotransposon inserted in sense and intronic
to Fgf1 (Supplemental Fig. S1A), a ligand for the oncogenic Fgfr1
receptor (Zhang et al. 2006). Further analysis showed that the
ETn element was present in the parental FVB genome (Keane
et al. 2011) and was homozygous in all of the animals studied
here (Supplemental Fig. S1A; Supplemental Table S2). Ameta-anal-
ysis of published RNA-seq data for HCC nodules obtained from
FVB mice (Hashimoto et al. 2015; Kress et al. 2016) did not, how-
ever, reveal an alternative Fgf1 promoter located in either of the
ETn element LTRs, as has been shown to occur previously for
LTRs located proximal to genes in Mdr2−/− liver nodules
(Hashimoto et al. 2015). More broadly, polymorphic L1 and
SINE insertions typically utilized an L1 EN motif, generated
TSDs, and incorporated a poly(A) tail (Supplemental Fig. S1B–D),
while ETn LTR insertions carried TSDs with an average length of
6 nt (Supplemental Fig. S1C), in agreement with previous reports
(Kaghad et al. 1985). These data highlight ongoing retrotranspo-
son activity in the Mdr2−/− mouse FVB.129 background strain.
We identified bymRC-seq four somatic nodule-specific L1 in-
sertions, which were confirmed by PCR validation using gDNA ex-
tracted fromnodule and tail samples, and validation productswere
capillary sequenced to characterize the TPRT-derived structural
hallmarks of each insertion (Fig. 1; Supplemental Fig. S2). In one
case (Fig. 1B), two nodules from the animal were analyzed, but
the insertion was specific to only one of these nodules. All four
L1 insertions were full-length (∼1.5–4.5 5′ UTR monomer units),
occurred at sites resembling the L1 endonuclease cleavage consen-
sus, bore 15- to 19-bp TSDs, and terminated in 3′ poly(A) tracts
ranging in length from 26 to 64 bp (Fig. 1; Supplemental Fig. S2;
Supplemental Table S2). Notably, we subsequently performed
45×WGS on five tumor nodes from the three mice in which these
full-length tumor-specific L1 insertions arose, to identify potential
5′ truncated L1 insertions that were not detected due to previously
described technical difficulties in sequencing the mouse L1 3′ end
(Richardson et al. 2017). As in our previous study, analysis ofWGS
data did not reveal any additional 5′ truncated insertions.
Three of the four L1 insertions (Fig. 1A,C,D) occurred within
the introns of genes (Agbl4, Plcb1, Syt17), and the fourth was inter-
genic (Fig. 1B; Supplemental Table S2). Analysis of their 5′ UTR
monomers indicated that three of the tumor-specific L1 insertions
were L1 TF elements, consistent with previous reports of spontane-
ous disease-causing L1 insertions in mice (Kingsmore et al. 1994;
Mulhardt et al. 1994; Kohrman et al. 1996; Takahara et al. 1996;
Perou et al. 1997; Naas et al. 1998; Yajima et al. 1999; Cunliffe et
al. 2001). Unexpectedly, the fourth L1 insertion belonged to the
L1GF subfamily, representing the first instance inwhich an endog-
enous de novo L1 insertion has been definitively identified as an
L1 GF subfamily element (Fig. 1A; Supplemental Fig. S2A).
For one L1 TF insertion, analysis of the 3′ capillary sequencing
PCR validation product revealed serial 3′ transductions (Fig. 1B;
Supplemental Table S2; Supplemental Fig. S2B). In this case, the
L1 was followed by a 52-bp poly(A) tract, a 16-bp non-homopoly-
mer sequence, a 33-bp poly(A) tract, a 682-bp unique sequence,
and terminated in a 38-bp poly(A) tract. Such 3′ transductions
occur when transcription of a donor L1 bypasses the native L1
polyadenylation signal and terminates at a downstream genomic
polyadenylation signal, so that the nascent L1mRNA incorporates
a unique genomic sequence tag that, upon retrotransposition, can
potentially be used to identify the donor L1 responsible for the in-
sertion (Holmes et al. 1994; Moran et al. 1996, 1999; Goodier et al.
2000; Pickeral et al. 2000; Macfarlane et al. 2013). Indeed, while
the first (16-bp) transduction could not be definitively mapped
to a donor L1, the second (682-bp) transduction identified a full-
length L1 TF element on Chromosome 1 absent from the C57BL/
6J reference genome but annotated as a structural variant in the
draft genome of the FVB mouse strain (Yalcin et al. 2012). This
donor L1 bore the 16-bp transduced sequence also noted in the tu-
mor-specific L1 insertion. Thus, we identified a specific donor L1
active in the context of liver cancer in mice, as identified similarly
in humans (Tubio et al. 2014).
We PCR-amplified this full-length donor L1 from tail DNA
from the mouse in which the nascent insertion was found and de-
termined that it contained two intact and functional open reading
frames (Fig. 2A).We also cloned the L1 into a retrotransposition in-
dicator plasmid containing a CMV promoter (Moran et al. 1996;
Naas et al. 1998; Wei et al. 2000) and tested its retrotransposition
efficiency in cultured HeLa cells. This L1 retrotransposed approxi-
mately eightfold more efficiently than L1spa, a previously-identi-
fied disease causing L1 TF insertion (Fig. 2B; Naas et al. 1998). Thus,
the L1 donor represents one of themost highly active natural L1 TF
elements tested in cultured cells to date (Naas et al. 1998; Martin
et al. 2008; Richardson et al. 2017).
The in vivo activity of a particular L1 copy depends upon its
epigenetic regulation in the relevant biological context, in addi-
tion to the enzymatic efficiency of its encoded proteins (Scott
and Devine 2017). Therefore, we used bisulfite sequencing to ana-
lyze the locus-specific DNAmethylation status of the donor L1, as
well as the overall methylation status of L1 TF promotermonomer-
ic sequences genome-wide (Fig. 2C,D), in all tumor and tail sam-
ples used in this study. Notably, in the locus-specific assay, each
sequenced clone represents a discrete donor L1 allele in a particular
cell. For themouse inwhich the tumor-specific insertionwas iden-
tified (animal #96109), the donor L1 locus-specific assay unexpect-
edly revealed significantly higher methylation levels in both
tumor nodules relative to the tail (Fig. 2E; Supplemental Fig. S3).
This pattern was evident for the methylation status of the donor
L1 across all tumor-tail pairs (P = 0.0004, paired t-test, two tailed)
(Supplemental Fig. S3). The methylation status of L1 TF monomer
sequenceswas, in contrast, indistinct inmost of the tumor nodules
relative to tail, with statistical significance (P = 0.0236, paired t-
test, two tailed) achieved due to exceptions to this trend (Fig. 2F;
Supplemental Fig. S3). However, examination of the locus-specific
methylation status of the donor L1 in the remaining tumor-tail
pairs revealed multiple clones with complete or near-complete
CpG demethylation in two nodules (animals #103699 and
#88218) (Supplemental Fig. S3), highlighting the propensity of
this locus to become demethylated during tumor development.
Thus, we hypothesize that the methylation status of the donor
L1 in animal #96109 may have been transiently permissive for
L1 expression in a subset of cells during the temporal window
when the insertion was generated but may have subsequently
undergone remethylation during clonal expansion of daughter
cells prior to tumor harvesting. Indeed, the presence of demethyl-
ated donor L1 sequences in tumors from other animals (Sup-
plemental Fig. S3) suggests that highly active L1s have the
potential to become epigenetically derepressed during murine tu-
mor development.
L1 retrotransposition in mammalian liver cancer
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Figure 1. Tumor-specific L1 insertions inMdr2−/− animals. For each insertion, the chromosomal location and orientation relative to the interrupted gene,
if applicable, are shown. L1 insertions are depicted as white rectangles, with monomer units represented as triangles within the 5′ UTR. Target-site dupli-
cations (TSDs) are shown as black arrows. Poly(A) tail length is indicated. The location and count of junction-spanningmRC-seq andWGS reads supporting
each insertion are depicted as red and white rectangles. The positions of PCR validation primers are shown as small arrows; where hemi-nested PCR was
used, the outer primer is depicted in grey and the inner primers are depicted in pink (5′ junction) and blue (3′ junction). At right, agarose gels containing the
5′ and 3′ junction validation products are shown. Templates are indicated above; for hemi-nested PCR, NTC 1st and NTC 2nd depict the no-template con-
trol reactions for the first and second rounds of PCR. Red arrows indicate the validating band. (A) A full-length (4.5 monomer units) L1 GF insertion in an-
tisense orientation within the fourth intron of the gene Agbl4 on Chromosome 4. (B) A full-length (2.5 monomer units) L1 TF insertion in an intergenic
region on Chromosome 1. This insertion bore two sequential 3′ transductions of 16 bp (gray line) and 682 bp (blue line). The 682-bp transduction indi-
cated a source L1 for the tumor-specific insertion (Donor 2) on Chromosome 1 (shown in blue). The original source L1 (Donor 1, shown in gray) responsible
for the 16-bp transduction could not be identified. (C) A full-length (1.5 monomer units) L1 TF insertion in sense orientation within the third intron of the
gene Plcb1 on Chromosome 2. (D) A full-length (1.5 monomer units) L1 TF insertion in sense orientation within the first intron of the gene Syt17 on
Chromosome 7.
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Figure 2. Retrotransposition competence and epigenetic characterization of an active donor L1. (A) Amino acid sequence comparison between the
L1MdTF_I/L1MdTF_II consensus sequence (Sookdeo et al. 2013), the L1 TF element L1spa (Naas et al. 1998), and the donor L1 responsible for the tu-
mor-specific 682-bp transduction-bearing L1 TF insertion (Fig. 1B). The locations of functional domains within ORF1p and ORF2p are depicted along
the L1MdTF_I/L1MdTF_II consensus. Amino acid changes within L1spa and the donor L1 relative to the L1MdTF_I/L1MdTF_II consensus are shown.
(B) (Top) Rationale of the cultured-cell retrotransposition assay (Moran et al. 1996; Wei et al. 2000). An L1 is tagged in its 3′ UTR with a reporter cassette
(in this case, a neomycin phosphotransferase gene) in antisense orientation relative to the L1, which is interrupted by an intron with splice donor and splice
acceptor sites in sense orientation relative to the L1. This arrangement ensures that, upon transfection of the construct into cultured cells, G418-resistant foci
arise only from cells which have undergone a successful round of retrotransposition. (Bottom) Results of the cultured cell retrotransposition assay.
Representative wells for each construct are depicted. JM105/L1.3 is a reverse transcriptase-deficient human L1, JM101/L1.3 is a wild-type human L1,
TGF21 is a previously-identified activemouse GF subfamily L1, L1spa is a previously identified disease-causingmouse TF subfamily L1, andDonor is the active
L1 TF subfamily element identified in this study. The histogramdepicts retrotransposition efficiency relative to TGF21. Data represent themean of three tech-
nical replicates ± SD. This assay was repeated three times (biological replicates) with similar results, and a representative assay is shown. (C) Experimental
design for analyzing the methylation status of both the donor L1 and the overall population of L1 TF members. The red boxes represent monomers and
the dotted lines represent the different CpG dinucleotides. CpG 96 and 111 are variable in the L1 TF population and are not present in the donor L1.
Blue primers are specific for the L1 TF family, while the green primer is specific to the junction of the donor L1. (D)Methylation level of the CpGdinucleotides
along the L1 sequence. Note that position 111 was present in <10% of the sequences and was completely unmethylated, and has not been taken into con-
sideration for the line drawing (redarrow). (E) Themethylationpatternof 50 randomproducts of locus-specific bisulfite sequencing reactions of thedonor L1
5′ junction. (F ) The overall L1 TF element population is depicted as in E. In E and F, methylated and unmethylated CpGs are represented by solid and empty
circles, respectively,while an “x”means aCpGwas not present. CpGdinucleotide positions are indicatedbelow the panels for “Tail”but canbe extrapolated
to the “HCC” panels. The overall percentage of methylated CpG dinucleotides is indicated above each cartoon.
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Liver tumor-specific L1 retrotransposition in human
hepatocellular carcinoma
In a previous study (Shukla et al. 2013), we analyzed 19 HCC pa-
tients infected with HCV or HBV and determined that L1 retro-
transposition is a feature of liver cancers of viral etiologies
(Supplemental Table S1). Here, to ask whether L1 retrotransposi-
tion is ubiquitous in liver cancers or is a particular feature of vi-
ral-driven tumorigenesis, we assessed L1 activity in human HCC
patients with a history of alcohol abuse. We performed RC-seq
on matched HCC and nontumor liver tissue samples from 25
additional patients with a history of alcohol abuse, as well as five
patients with chronic HCV infection and two patients with chron-
ic HBV infection, to bring the total of viral HCC cases investigated
by RC-seq to 26 (Supplemental Table S1). In the full data set of 51
HCC patients, and the 10 ICC patients discussed below, we identi-
fied 3055 polymorphic retrotransposon insertions, including
414 events not annotated previously (97 L1, 312 Alu, and five
SVA) that, collectively, carried the expected hallmarks of TPRT
(Supplemental Fig. S1E–G).
In the 32 newHCC samples, we also identified eight highly 5′
truncated tumor-specific L1 insertions, which were concentrated
in three patients with a history of alcoholism (HCC.58, five inser-
tions; HCC.16, two insertions; HCC.99, one insertion) (Fig. 3;
Supplemental Figs. S4A–E, S5; Supplemental Table S2). No tu-
mor-specific insertions were identified in the seven additional
HBV/HCV cases. Six of the eight insertions bore TSDs ranging in
size from 3 to 16 bp, while two lacked TSDs and featured small ge-
nomic deletions; all eight insertions occurred at sites resembling
the consensus L1 endonuclease motif and ended in poly(A) tracts
of 14–121 bp. One insertion was located in the seventh intron of
the geneKHDRBS2, in antisense orientation (Fig. 3A), while anoth-
er occurred in the ninth intron of the SLC10A7 gene, also in anti-
sense orientation (Supplemental Fig. S4A). The remaining six
insertions were intergenic (Fig. 3C,D; Supplemental Fig. S4B–E).
KHDRBS2 is an RNA-binding protein thought to regulate al-
ternative splicing (Iijima et al. 2014). To investigate the ability of
intronic tumor-specific L1 insertions to influence gene expression,
we performed qRT-PCR using RNA extracted from tumor and non-
tumor liver tissue from the patient bearing the KHDRBS2 L1 inser-
tion (HCC.58) and nine other HCC tumor/nontumor tissue pairs.
We found that the only individual to present a significant differ-
ence in KHDRBS2mRNA levels between tumor and nontumor liv-
er, when compared to each of the remaining individuals (P < 0.05,
A
DC
B
Figure 3. Tumor-specific L1 insertions in HCC patients with a history of alcoholism. For each insertion, the chromosomal location and orientation relative
to the interrupted gene, if applicable, are shown. L1 insertions are depicted as white rectangles; the truncation point of each insertion is indicated. Target-
site duplications (TSDs) are shown as black arrows; deletions of genomic DNA are shown as white triangles. Poly(A) tail length is indicated. Where appli-
cable, untemplated nucleotides at the 5′ L1-genome junction are indicated as a blue rectangle. The location and count of junction-spanning RC-seq reads
supporting each insertion are depicted as red and white rectangles. The positions of PCR validation primers are shown as small arrows. Where empty-filled
validation was successful, primers are indicated in red. Where junction PCRs were employed, primers are depicted in pink (5′ junction) and blue (3′ junc-
tion). Where nested or hemi-nested PCR was necessary, the outer primer(s) are depicted in gray and the inner primers are depicted in color. Agarose gels
containing the empty/filled or 5′ and 3′ junction validation products are shown. Templates are indicated above; for nested and hemi-nested PCR reactions,
NTC 1st and NTC 2nd depict the no-template control reactions for the first and second rounds of PCR. Red arrows indicate the validating band. (A) A
5′ truncated L1 insertion in antisense orientation within the seventh intron of the gene KHDRBS2, detected in patient HCC.58 tumor. (B) KHDRBS2
mRNA abundance relative to TBP measured by qRT-PCR using RNA extracted from 10 HCC patient tumor (red) and nontumor (light blue) sample pairs,
including patient HCC.58. Data represent the mean of three technical replicates ± SD. For each patient, values were normalized to the nontumor mean.
Significance values were obtained via a two-way ANOVA followed by Tukey’s post hoc analysis. (C,D) Two additional tumor-specific 5′ truncated L1 inser-
tions, their genomic locations and structural hallmarks, and validating PCR products are depicted as described above.
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two-way ANOVA with Tukey’s post hoc analysis) was patient
HCC.58, with a 77% reduction in KHDRBS2 expression in tumor
(Fig. 3B). Notably, this qRT-PCR assay captured the expression of
both major KHDRBS2 protein-coding splice isoforms at an
exon–exon junction upstream of the L1 insertion. Repeated at-
tempts to robustly measure KHDRBS2 expression at an exon–exon
junction downstream from the L1 insertion were unsuccessful,
and the gene was not detected by a previously published ge-
nome-wide survey of promoter usage (Hashimoto et al. 2015).
Thus, consistentwithprevious reports,we find that a tumor-specif-
ic intronic L1 insertion can coincide with down-regulation of host
gene expression (Lee et al. 2012; Shukla et al. 2013; Helman et al.
2014; Tubio et al. 2014; Carreira et al. 2016), but the mechanism
for this potential dysregulation remains unresolved.
Liver tumor-specific L1 retrotransposition and comprehensive
genomic analysis of intra-hepatic cholangiocarcinoma
We next asked whether tumor-specific L1 insertions arise in intra-
hepatic cholangiocarcinoma, a liver malignancy originating from
the epithelial cells lining the bile ducts (Serafini and Radvinsky
2016). Incidence of ICC is rapidly increasing worldwide and ac-
counts for 10%–20% of primary hepatic cancers (Gupta and
Dixon 2017), and ICC is associated with a poorer 5-yr survival
rate than HCC (Lang et al. 2007; Rizvi and Gores 2013). We ana-
lyzed tumor/nontumor sample pairs from 10 ICC patients by RC-
seq and ∼40× WGS. The WGS data also allowed us to perform a
comprehensive genomic analysis (Fig. 4A) to assess the frequency
of tumor-specificmutations and the prevalence of tumor and non-
tumor cells within each sample. We identified between 1.39 and
6.28mutations permegabase in eight of the 10 ICC tumor/normal
pairs analyzed (Supplemental Table S3) and observed a range of
different variant allele fraction distributions (Supplemental Figs.
S6, S7). The remaining two ICC tumors (ICC.55 and ICC.63)
either had very high levels of nontumor sample sequenced or the
samples provided were both from the same tissue sample, given
the relative lack of deleterious somatic mutations detected (Sup-
plemental Fig. S7).
Bioinformatic analysis revealed three tumor-specific L1
insertions for patients ICC.33, ICC.64, and ICC.75, which were
PCR-validated and fully characterized (Supplemental Fig. S8; Sup-
plemental Table S2). All three insertions were highly 5′ truncated
and occurred in intergenic regions. Two insertions (Fig. 4B;
Supplemental Figs. S4F, S8A,B) did not bear TSDs and instead ex-
hibited small deletions of target-site DNA (1 and 2 bp) consistent
with second-strand cleavage upstream of rather than downstream
from the first-strand L1 endonucleolytic nick (Gilbert et al. 2002,
2005). Indeed, as these insertions occurred at perfect (5′-TT/
AAAA-3′) and near-perfect (5′-AT/AAAA-3′) L1 endonuclease cleav-
age motifs and incorporated ∼61- and ∼96-bp poly(A) tracts, they
likely represent bona fide TPRT events, despite lacking TSDs.
The third ICC tumor-specific L1 insertion (Fig. 4C; Sup-
plemental Fig. S8C), found in patient ICC.75, bore 16-bp TSDs,
occurred at a near-perfect L1 endonuclease cleavage motif (5′-
TT/AGAA-3′), and incorporated a short (18-bp) 3′ transduction
flanked by 13- and 28-bp poly(A) tracts. Analysis of the 3′ trans-
duced sequence identified a donor L1 on Chromosome 22 and
intronic to the gene TTC28. Recent studies of 3′ transduction-bear-
ing L1 insertions in tumor samples pointed to this element as a
highly active donor L1 in human tumor cells (Pitkanen et al.
2014; Tubio et al. 2014; Paterson et al. 2015; Philippe et al. 2016;
Gardner et al. 2017). We therefore performed targeted bisulfite se-
quencing of the complete donor L1 promoter region, which was
significantly demethylated in patient ICC.75 tumor compared to
matched nontumor liver (P < 0.0001, paired t-test, two tailed)
(Fig. 4C). Despite this difference, we observed numerous fully
demethylated clones in both the tumor and nontumor liver, sug-
gesting this specific donor L1 may have been de-repressed prior
to, or as part of, liver dysplasia.
We next analyzed the ICC WGS data to identify deleterious,
non-retrotransposition-mediated mutations driving oncogenesis
(Supplemental Tables S4, S5). Most of the ICC genomes analyzed
had high levels of rearrangement reflected by copy number varia-
tion, and inter- and intra-chromosomal variation. In particular,
high levels of loss and rearrangement of the p armof Chromosome
1 involving the telomere were seen in seven out of eight ICC tu-
mors with high tumor cellularity. In patients ICC.75 and ICC.30,
high numbers of SV predictions were clustered in Chromosome
1q, across Chromosome 7 in ICC.64, andChromosome 9p encom-
passing the tumor suppressor CDKN2A in ICC.17 (Supplemental
Fig. S7). Inter-chromosomal rearrangements clustering on Chro-
mosome 4 of ICC.17 and throughout the genome of ICC.64 (nota-
blyonChromosome17) added to a picture of highplasticity in ICC
genomes (Supplemental Fig. S9).
Among the spectrum of tumor-specific genomic aberrations,
we identified multiple samples with likely loss-of-function muta-
tions or deletions in tumor suppressor genes found tobe frequently
mutated in previous genomic studies of ICC and other cholangio-
carcinomas (Chan-On et al. 2013; Jiao et al. 2013; Zou et al. 2014;
Nakamura et al. 2015; Farshidfar et al. 2017; Jusakul et al. 2017).
Examples include the tumor suppressor genes ARID1A, BAP1, and
PBRM1, which encode chromatin remodeling factors (Thompson
2009; Scheuermann et al. 2010; Wilson and Roberts 2011; Wu
and Roberts 2013). In addition,multiple samples contained inacti-
vating mutations in the tumor suppressor NF2, which encodes a
scaffold protein that links extracellular stimuli and intra-cellular
signaling pathways involved in cell proliferation and survival
(Petrilli and Fernandez-Valle 2016).
The resolution provided via WGS allowed us to identify sev-
eral likely biallelic losses of known ICC driver genes: For example,
we observed possible loss of both ARID1A alleles in the tumors of
patients ICC.1, ICC.64, ICC.75, and ICC.81 through a com-
bination of Chromosome 1p loss, localized SVs, frameshift, and
stop-gain mutations. When the Chromosome 1p CNV profile
was taken into account, all eight tumors were likely to have lost
at least one allele of ARID1A (Supplemental Fig. S7), underscoring
its importance as a tumor suppressor in ICC. Additionally, in ac-
cordance with previous observations (Jiao et al. 2013), we observe
frequent loss of at least one allele on Chromosome 3p surround-
ing the BAP1 and PBRM1 genes (6/8 tumors), further highlight-
ing the importance of chromatin remodeling factors in this
tumor type.
In addition to loss-of-functionmutations in genes previously
implicated in cholangiocarcinomas, we also uncovered inactivat-
ing mutations in classical tumor suppressor and proto-oncogenes.
We identified two patients (ICC.75, ICC.81) with tumor-specific
deletions on Chromosome 13q involving the BRCA2 and RB1
genes. Notably, ICC.81 likely has a biallelic loss of BRCA2 due
to an additional frameshift indel mutation in BRCA2 (I1924fs)
detectable in the nontumor sample. In addition, two patients
(ICC.75 and ICC.81) have oncogenic mutations in BRAF (G466A
and G466R), two have IDH2 mutations (R172W and R172M),
ICC.64 has a KRAS G12D mutation, and ICC.33 has an amplifica-
tion involving KRAS. Finally, we identified recurrent mutations in
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Figure 4. ICC patient tumor mutational landscape, including tumor-specific L1 insertions. (A) Circos diagram (Krzywinski et al. 2009) summarizing ICC
somatic mutations including copy number gains (red) and losses (blue), intra-chromosomal (colored by chromosome pair) and inter-chromosomal (red =
duplication, blue = deletion, green = inversion) rearrangements. Rearrangements shown are those that intersect genes identified in prior ICC studies or pre-
sent in the COSMIC Cancer Gene Census. L1 insertions are highlighted in red text labels on the outside of the circle, and selected genes with somatic mu-
tations are highlighted with blue labels. Selected somaticmutations (SNVs and INDELs) are shown as yellow dots with highlights superimposed on the copy
number variation rings. (B,C) Detailed characterization of two intergenic and 5′ truncated tumor-specific L1 insertions. For each insertion, the chromosom-
al location is shown. L1 insertions are depicted as white rectangles; the truncation point of each insertion is indicated. The location and count of junction-
spanning RC-seq and WGS reads supporting each insertion are depicted as red and white rectangles. Target-site duplications are shown as black arrows;
deletions of genomic DNA are shown as white triangles. Poly(A) tail length is indicated. The positions of PCR validation primers are shown as small arrows.
Where empty-filled validation was successful, primers are indicated in red. Where junction PCRs were employed, primers are depicted in pink (5′ junction)
and blue (3′ junction). Where hemi-nested PCR was necessary, the outer primer(s) are depicted in gray and the inner primers are depicted in color. Agarose
gels containing the empty/filled or 5′ and 3′ junction validation products are shown. Templates are indicated above; for hemi-nested PCR reactions, NTC1st
and NTC 2nd depict the no-template control reactions for the first and second rounds of PCR. Red arrows indicate the validating band. The L1 insertion
shown in C carried an 18-bp 3′ transduced sequence implicating a donor L1 (shown in blue) located in the TTC28 gene on Chromosome 22. The meth-
ylation state of this specific donor L1 (below) was determined via targeted bisulfite sequencing of its promoter CpG island (primers are depicted in C as black
arrows). Each cartoon represents 50 random, nonidentical sequences matching the donor L1 (black circle, methylated CpG; white circle, unmethylated
CpG; “x,” absent) obtained from patient ICC.75 nontumor liver and matched tumor.
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possible, but less well-characterized, cancer drivers in multiple pa-
tients, including CDK6, CDK9, NEK9, and EPHA2. This genome-
wide view of the ICC mutation landscape highlights mutational
processes underpinning ICC, where de novo L1 insertions occur
alongside other forms of genomic aberration in these highly mu-
tated tumors.
Discussion
Here, we have conducted an extended analysis of L1 insertions
arising in both mouse and human hepatocarcinogenesis of multi-
ple etiologies. We validated each tumor-specific insertion thor-
oughly by PCR, clearly establishing the hallmarks of bona fide L1
retrotransposition by TPRT. We find that L1 retrotransposition is
a feature of hepatocarcinogenesis in mice and humans, suggesting
similar L1 dysregulation in cancer genomes across species. To our
knowledge, this is the first report of endogenous L1 mobilization
being observed directly in a nonhuman cancer, with the possible
exception of an L1 mutation found proximal to MYC in canine
transmissible venereal tumors and arising either in the dog germ-
line or the somatic evolution of the original tumor (Murgia et al.
2006). Combined with a previous report of L1 and IAP protein ex-
pression in tumors obtained from aMycmurine liver cancermodel
(Wylie et al. 2016), our results highlightmouse as a suitable system
to study L1 activity in oncogenesis and cancer progression, which
may be useful for future studies that are not feasible using human
patient samples. Indeed, the finding that Mdr2−/− mice accom-
modate tumor-specific L1 retrotransposition is particularly inter-
esting, as these genomic alterations occur alongside massive
gene amplifications (Iannelli et al. 2014). All four tumor-specific
mouse L1 insertions were full-length and therefore likely to retain
retrotransposition competence, allowing them to serve as poten-
tial donor L1s for subsequent tumor-specific retrotransposition
events, as previously observed in human malignancies (Tubio
et al. 2014; Gardner et al. 2017).
Of the four tumor-specific mouse L1 insertions, three oc-
curred in introns and the remaining example was intergenic.
None of the three affected genes (Agbl4, Plcb1, Syt17) is well estab-
lished to play a role in HCC tumorigenesis, although Plcb1, a reg-
ulator of signal transduction, has been reported as both a cancer
marker and suppressor (Guerrero-Preston et al. 2014; Tan et al.
2015; Li et al. 2016). No exonic tumor-specificmouse L1 insertions
were detected. In this regard, the genomic distribution of mouse
tumor-specific L1 insertions, although involving at this stage a
handful of events, resembles patterns reported for human cancers,
where L1 insertions found in exons of known cancer genes (Miki
et al. 1992; Helman et al. 2014; Scott et al. 2016) are far rarer
than such events located in introns (Lee et al. 2012), including
the example of the ST18 oncogene (Shukla et al. 2013; Rava
et al. 2017) and a more recent instance in the tumor suppressor
gene BRCA1 (Tang et al. 2017). Although the oncogenic impact
of intronic tumor-specific L1 insertions is more difficult to mech-
anistically assess than exonic events, they are also far more numer-
ous and are therefore a potentially important and underexplored
class of mutation encountered in mammalian cancers (Scott and
Devine 2017).
The prevalence of full-length L1 insertions detected inmouse
tumors, as well as the lack of 5′ truncated and inverted/deleted
events in this context, is also noteworthy. Used in isolation, the
mRC-seq approach can overlook 5′ truncated or inverted/deleted
L1 insertions due to (1) the position of the mRC-seq probes at
the L1 5′ and 3′ termini, and (2) low efficiency Illumina sequenc-
ing across the mouse L1 3′ end (Richardson et al. 2017). However,
whole-genome sequencing, which efficiently detects the 5′ end of
both full-length and rearranged L1 insertions, even if the corre-
sponding 3′ end is not detected, was applied to five Mdr2−/− nod-
ules and did not reveal any insertions not found bymRC-seq, as we
found was also the case in our previous study of heritable L1 inser-
tions in extended mouse pedigrees (Richardson et al. 2017).
Hence, at least somemouse L1 families may be highly predisposed
to generate full-length offspring L1 insertions in the germline
(Hardies et al. 2000; Richardson et al. 2017) as well as in cancer
cells. In contrast, L1 insertions detected in human tumors are pre-
dominantly 5′ truncated (Iskow et al. 2010; Lee et al. 2012; Solyom
et al. 2012; Shukla et al. 2013; Helman et al. 2014; Tubio et al.
2014; Doucet-O’Hare et al. 2015, 2016; Ewing et al. 2015; Paterson
et al. 2015; Rodic et al. 2015; Scott et al. 2016) and involve struc-
tural rearrangements at a higher frequency than for L1 insertions
arising in the human germline (Gardner et al. 2017). These differ-
ences are apparent even among hominids. For example, the rate of
germline L1 5′ inversion appears to be lower in chimpanzee than
in human (Gardner et al. 2017). Whether these observations re-
flect species-specific differences in the enzymatic properties of
L1s or the cellular environment inwhich retrotransposition events
occur, including host factors such as the APOBEC (also known as
AID) family proteins that are more diverse in humans than in ro-
dents (Goodier 2016), remains to be determined.
Furthermore, we report the identification of a specific donor
mouse L1 TF element responsible for a tumor-specific L1 insertion
and demonstrate its retrotransposition competence in a cultured
cell assay, implicating this L1 locus as active in cancer. Indeed, pro-
motermethylation analysis of the donor L1 across allMdr2−/−nod-
ules revealed completely unmethylated copies in two nodules
other than the one in which the insertion was found but not in
any of thematched tail samples, indicating that this L1may recur-
rently become derepressed in the context of oncogenesis and tu-
mor progression. Future identification of 3′ transduction events
arising from the same active donor L1 in additional mouse malig-
nancies may further implicate this locus as particularly “hot” in
the context of murine tumorigenesis, as has been found in human
cancers (Tubio et al. 2014; Scott et al. 2016).We also report the first
example of a de novo L1GF retrotransposition event in vivo.While
some L1 GF elements are polymorphic amongmouse strains, indi-
cating recent germlinemobilization, and L1GF elements retain ret-
rotransposition capability in cultured cell assays (Goodier et al.
2001), all previously described disease-causing mouse L1 inser-
tions where the subfamily could be determined were identified
as TF elements (Kingsmore et al. 1994; Mulhardt et al. 1994; Kohr-
man et al. 1996; Takahara et al. 1996; Perou et al. 1997; Naas et al.
1998; Yajima et al. 1999; Cunliffe et al. 2001). Indeed, recent work
from our laboratory identified 11 de novo L1 insertions occurring
in the germline or early embryo in C57BL/6J mice, and all of these
insertions belonged to the L1 TF subfamily (Richardson et al.
2017).Whether different mouse L1 subfamilies are prone tomobi-
lization in particular cell types or developmental contexts remains
to be determined. Alternatively, the activity of different L1 sub-
family elements may be influenced by the genetic background of
the inbred mouse strain analyzed (Maksakova et al. 2006; Akagi
et al. 2008; Nellaker et al. 2012).
Along similar lines, we identified polymorphic ETn (but not
IAP) LTR retrotransposon insertions present in ourmice but absent
from the C57BL/6J reference genome, and some of these were not
detected in themouse strains contributing the genetic background
of the animals in our study (FVB and 129) or any other inbred
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mouse strain analyzed. This result is in contrast to previous work
from our lab, wherein we did not detect any nonreference poly-
morphic ETn or IAP LTR retrotransposon insertions in wild-type
C57BL/6J mice (Richardson et al. 2017). All animals in the present
study also harbored an intact ETn element inserted in Fgf1 and
found in the parental FVB mouse genome. Although we did not
find evidence linking transcription of the ETn LTRs with Fgf1 ex-
pression, this result shows that different mouse strains can harbor
polymorphic TE variants in oncogenic pathways, as we suggested
previously for human individuals (Shukla et al. 2013).
In addition to demonstrating L1 activity inmouse hepatocar-
cinogenesis, we report tumor-specific human L1 mobilization in
HCC from patients with a history of alcoholism. We previously
identified tumor-specific L1 mobilization in HCC of viral etiology
(HBV or HCV), raising the possibility that viral infection in-
fluenced susceptibility to L1 mobilization (Shukla et al. 2013).
However, the analysis of these new results in combination with
those from our previous study (Shukla et al. 2013) indicates that
liver cancer etiology does not appear to be a predictor of L1 activity
(12 insertions among 26 HCC tumors of viral etiology, eight inser-
tions among 25 HCC tumors of alcoholic etiology). We also
describe an intronic L1 insertion into the gene KHDRBS2 which
correlates with tumor-specific KHDRBS2 down-regulation, rein-
forcing the observation that L1mutagenesismay result in dysregu-
lation of cellular genes in a tumor-specific manner (Lee et al. 2012;
Shukla et al. 2013).
Finally, we report that L1 activity in human liver malignan-
cies is not restricted to HCC, as we identified three tumor-specific
L1 insertions among 10 ICC patients. Among these, one insertion
originated from a donor L1 on Chromosome 22 previously found
to be responsible for tumor-specific L1 insertions in other human
cancer types (Pitkanen et al. 2014; Tubio et al. 2014; Paterson et al.
2015). An increasing body of evidence suggests that a particular
subset of retrotransposition-competent L1 loci tend to be recur-
rent contributors to genomic instability in human malignancies
and cancer cell lines (Tubio et al. 2014; Philippe et al. 2016;
Scott et al. 2016; Gardner et al. 2017). Indeed, here we found
that the promoter region of the TTC28 donor L1 was largely de-
methylated in both nontumor liver and matched ICC tumor cells,
as a prior study found for a Chromosome 17 donor L1 responsible
for APC exon mutagenesis in a colorectal cancer patient (Scott
et al. 2016). These findings together raise the prospect of multiple
donor L1 loci being active in the pre-neoplastic tissues of cancer
patients.
Although all three tumor-specific insertions in the ICC pa-
tients studied here were intergenic and therefore unlikely to exert
a significant functional impact, we also analyzed WGS data from
the ICC samples to characterize the spectrum of deleterious tu-
mor-specific mutations occurring in these patients. Our results re-
vealed frequent mutation of several genes, particularly ARID1A,
known to be recurrently mutated in ICC and other cholangiocar-
cinomas, as well as aberrations in classical tumor suppressor and
proto-oncogenes. Furthermore, we identified multiple mutations
in a handful of genes associated with tumorigenic processes
(AMER1, NEK9, NAP1L1, and GAB2) but not previously described
as recurrentlymutated in ICC. Thus, analysis of additional patients
and functional experiments may reveal a recurrent role for these
factors in ICC and other cholangiocarcinomas. Together, our re-
sults indicate that L1mobilization is a distinguishing characteristic
of epithelial cancers of diverse etiologies and across species, dem-
onstrating that this phenomenon is an intrinsic component of ep-
ithelial tumorigenesis.
Methods
Animals
Founders of the FVB.129P2-Abcb4tm1Bor (Mdr2−/−) strain were pur-
chased from The Jackson Laboratory and maintained by mating
homozygous siblings. Colonies were maintained under specific
pathogen-free conditions. A portion of each nodule and control
sample (tail) was snap-frozen for DNA extraction. Furthermore, a
portion of each HCC specimen was histologically assessed after
overnight fixation in 4% formaldehyde and paraffin inclusion.
Slides were finally counterstained with hematoxylin andmounted
with Eukitt. Frozen tissue samples were homogenized with a
gentleMACS Dissociator (Miltenyi Biotec) before column extrac-
tion. Genomic DNA was extracted using the DNeasy Blood and
Tissue Kit (Qiagen) according to the manufacturer’s protocol for
all samples.
All analyzed samples were inspected by a mouse pathologist.
Tumor growth in Mdr2−/− livers is multicentric; gross detectable
masses are often very heterogeneous resulting from the collision
ofmultiple contiguous hepatocellular proliferations with different
histologic features and grades. In addition, there is a tendency for
hepatocellular carcinoma to developwithin an adenoma (as foci of
tumor progression). Given these peculiar characteristics of tumor
growth in Mdr2−/− mice, the histological composition of gross
detectable hepatic nodules was semiquantitatively determined
based on reported classification criteria (Thoolen et al. 2010).
Human patient samples
Snap-frozen tissue samples were obtained from 32 patients with
HCC induced by a history of alcoholism (25), chronic HBV infec-
tion (2), and chronicHCV infection (5), and 10 patientswith intra-
hepatic cholangiocarcinoma (ICC) (Supplemental Table S1). These
samples are in addition to those HCC samples previously analyzed
by Shukla et al. (2013), comprisingHBV (10) andHCV (9) HCC eti-
ologies (Supplemental Table S1). All patients gave written in-
formed consent. Specimens were obtained after surgical resection
or from liver explants at transplantation. For each patient, we an-
alyzed tumor and distal nontumor liver tissue (T/NT pairs).
Library preparation and sequencing
ForMdr2−/−mouse samples, genomic DNA was extracted from tu-
mor nodules and tails using standard phenol-chloroform extrac-
tion. Illumina libraries were prepared as described in Richardson
et al. (2017) using Illumina TruSeq DNA LT library preparation
kits incorporating an insert size of ∼450–550 bp. Twenty-two total
barcoded libraries were pooled, subjected to the mRC-seq enrich-
ment protocol as described (Richardson et al. 2017), and se-
quenced on an Illumina MiSeq platform using 600 cycle kits
generating 114,638,158 2 × 300-bp paired-end reads. A subset of
five pre-enrichment libraries prepared from tumor DNA (Sup-
plemental Table S1) was subjected to ∼45× whole-genome se-
quencing (Macrogen) on an Illumina HiSeq X Ten platform,
generating 2,272,895,769 2 × 150-bp paired-end reads (Supple-
mental Table S1).
For human HCC patient samples, genomic DNA was extract-
ed from tumor and nontumor liver tissue using standard phenol-
chloroform extraction. Illumina libraries were prepared as de-
scribed (Shukla et al. 2013) using Illumina TruSeq DNA LT library
preparation kits incorporating an average insert size of 220 bp.
Seventy total barcoded libraries were pooled, subjected to RC-seq
enrichment as described in Shukla et al. (2013), and sequenced
on an Illumina HiSeq 2500 platform (AmbryGenetics), generating
1,635,587,606 2 × 150-bp paired-end reads.
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For human ICCpatient samples, total DNAwas isolated using
the DNeasy Blood and Tissue Kit (Qiagen). Illumina libraries were
prepared as described (Shukla et al. 2013) using Illumina TruSeq
DNA LT library preparation kits incorporating an average insert
size of 250 bp. Barcoded libraries were pooled, subjected to RC-
seq enrichment as described (Upton et al. 2015), and sequenced
on an Illumina HiSeq 2500 Platform (Ambry Genetics) generating
255,239,605 2 × 150-bp paired-end reads.
Human ICC genomic DNA samples were independently sub-
jected to library preparation by Macrogen, using Illumina TruSeq
DNANano LT library preparation kits incorporating an average in-
sert size of 350 bp. Libraries were subjected to ∼40× WGS on an
Illumina HiSeq X 10 platform, generating 8,482,986,041 2 × 150-
bp paired-end reads.
Human ICC WGS analysis
Reads were aligned to the human genome reference sequence
(hg19 build) with BWA-MEM (Li 2013), duplicates were mark-
ed with Picard MarkDuplicates (http://broadinstitute.github.io/
picard), and indel realignment was carried out with GATK
(DePristo et al. 2011). Quality assessment via FastQC identified
no issueswith sequence quality or content, duplication, overrepre-
sented sequences or k-mers. Point mutations (SNVs and indels)
were detected with MuTect 2 (Cibulskis et al. 2013), and structural
rearrangements were detected using Manta (Chen et al. 2016).
CNV profiles were derived from normalized tumor vs. normal
read depth in 150-kbp windows using a Python script deposited
on GitHub (https://gist.github.com/adamewing/70c8819f6f1eec
0ffbdafa6210f0f677) and also available in SupplementalMaterials.
TE insertion detection
WGS- and RC-seq-aligned BAMs (mouse: mm10 build, human:
hg19 build) were processed with TEBreak (https://github.com/
adamewing/tebreak and Supplemental Materials) to detect nonre-
ference transposable element insertions. Further post-filtering on
detected insertions was performed as follows: Reads supporting
TE insertions must align to TE consensus sequences at ≥90% iden-
tity and to the reference genome at ≥99% identity. TE insertion
calls must be supported by at least eight split reads and eight dis-
cordant read pairs for mouse and at least four split reads and
four discordant read pairs for human. At least 50% of all split reads
and discordant reads surrounding an insertion call must be
attributable (i.e., remappable) to that insertion. For SINEs, inser-
tions detected with 5′ truncations of more than 1 bp, or with 3′
truncations, or presenting low complexity TSDs (e.g., all “A” or
“T” bases), or lacking TSDs, were excluded. Nonreference insertion
calls were annotatedwith knownnonreference insertion polymor-
phisms. For human, this annotation is derived from 15 previous
studies includedwith TEBreak (Ewing 2015). Formouse insertions,
the nonreference annotations are derived from running TEBreak
on 40 inbred mouse strains available through the Sanger Mouse
Genomes Project (http://www.sanger.ac.uk/science/data/mouse-
genomes-project) (Keane et al. 2011), which is also included
with TEBreak. To ensure that use of the hg19 human reference ge-
nome assembly, rather than hg38, did not impact our conclusions,
we remapped the genomic consensus sequences for tumor-specific
insertions (Supplemental Table S2) to the hg38 assembly. We
found that the number of results did not change, the relative chro-
mosome positions were consistent with results obtained via the
UCSC liftOver tool, the gene annotations did not change, and
all sites mapped uniquely. Therefore, remapping to hg38 would
be highly unlikely to alter the results or conclusions that we
have highlighted.
Validation and structural characterization of TE insertions
RC-seq, mRC-seq, and WGS reads, and TEBreak breakpoint con-
sensus sequences, for putative tumor-specific insertions were
manually inspected using SerialCloner (http://serialbasics.free.fr/
Serial_Cloner.html) and the UCSC genome browser BLAT tool
(Kent 2002). Primers to test de novo L1 insertions were designed
in the 5′ and 3′ flanking genomic DNA regions (Supplemental
Table S2). The complete ETn insertion found in Fgf1was amplified
with the primers TCCAGCCTCCTCCTCATCTA (forward) and
GGAAGAGGGGGCACTAAACT (reverse). Oligonucleotides were
obtained from Integrated DNA Technologies).
Empty-filled validation PCRs were carried out using the
Roche Expand Long-Range PCR system (Roche) with primers spe-
cific to the 5′ and 3′ genomic sequence flanking putative inser-
tions. 5′ and 3′ junction validation PCRs were carried out using
theMyTaq PCR system (Bioline) using the appropriate flanking ge-
nomic primer paired with a primer internal to the L1 sequence;
where necessary, hemi-nested and fully nested PCR reactions
were carried out using appropriately designed genomic and L1-spe-
cific primers. Products were visualized on 1%–2.5% agarose gels
stained with SYBR Safe stain (Life Technologies). Bands matching
the expected size or present in tumor samples and absent from the
corresponding control tissue were excised, purified using Qiagen
MinElute gel extraction kits (Qiagen), and either capillary se-
quenced directly or cloned into and capillary sequenced from
pGEM-T Easy (Promega) or TOPO-XL (Life Technologies) vectors.
Validation product sequences were manually analyzed and in-
spected for the structural hallmarks of L1 retrotransposition.
Plasmid constructs
pTN201 (Naas et al. 1998) is a neomycin-based L1 retrotransposi-
tion indicator plasmid containing L1spa, a wild-type mouse L1
TF element in the pCEP4 plasmid backbone. TGF21 (Goodier
et al. 2001) is a neomycin-based L1 retrotransposition indicator
plasmid containing TGF21, a wild-type mouse L1 GF element in
the pCEP4 plasmid backbone. pJM101/L1.3 (Dombroski et al.
1991; Sassaman et al. 1997) is a neomycin-based L1 retrotranspo-
sition indicator plasmid containing L1.3, a wild-type human L1
in the pCEP4 plasmid backbone, and pJM105/L1.3 (Wei et al.
2000) is a neomycin-based L1 retrotransposition indicator plasmid
containing L1.3 with an inactivating mutation in the L1 reverse
transcriptase active site in the pCEP4 plasmid backbone.
Generation of a mouse donor L1 reporter construct
The mouse donor L1 TF element was PCR-amplified from mouse
#96109 tail genomic DNA using the Roche Expand Long-Range
PCR systemwith primers located in the 5′ and 3′ flanking genomic
DNA; the 5′ forward primer incorporated a NotI restriction site
(fwd: aaaaaaGCGGCCGCcaagaatgcccaGTTCAGCC; rev: GAATTG
GGTTGGGTATTCTTCC). Ten replicate PCR reactions were per-
formed in parallel; to determine the sequence of the donor L1,
the products were pooled and capillary sequenced using primers
located at ∼500-bp intervals along the L1 TF consensus sequence.
The donor L1 PCR product was also cloned into a neomycin-based
L1 retrotransposition indicator plasmid as described in Richardson
et al. (2017). Ten independent clones were sequenced; the L1
shown in Figure 2B contained three PCR-induced silent mutations
and no nonsynonymous mutations relative to the sequence de-
rived from the pooled PCR products.
Cultured cell retrotransposition assay
Cultured cell retrotransposition assay: HeLa-JVM cells were seeded
at 5 × 103 cells/well in six-well plates and transfected using
L1 retrotransposition in mammalian liver cancer
Genome Research 649
www.genome.org
 Cold Spring Harbor Laboratory Press on May 3, 2018 - Published by genome.cshlp.orgDownloaded from 
FuGENE HD Transfection Reagent (Promega) at a ratio of 4 µL to 1
µg plasmid DNA. G418 selection (400 µg/mL) was initiated at 72 h
post-transfection and carried out for 12 d (Wei et al. 2000).
Assays for transfection efficiency were performed in parallel
by cotransfection of pCAG-EGFP with L1 reporter plasmids. At
48 h post-transfection, cells were subjected to flow cytometry on
a CytoFLEX flow cytometer (Beckman-Coulter) at the Translation-
al Research Institute Flow Cytometry Core. The percentage of
EGFP positive cells for each L1 reporter construct was used to nor-
malize the G418-resistant colony counts obtained in the retro-
transposition assay (Wei et al. 2000; Kopera et al. 2016).
Mouse L1 methylation analysis
Genomic DNA from mouse tumor and tail samples was subject-
ed to bisulfite conversion using the EZ DNA Methylation-
Lightning Kit (Zymo Research), following the manufacturer’s
instructions. To amplify L1 TF monomers genome-wide, PCR am-
plification was performed using the MyTaq DNA Polymerase PCR
kit (Bioline) with primers targeting the internal sequence of the
L1 TF monomer (fwd: GTTGAGGTAGTATTTTGTGTGGGT; rev:
TTCCAAAAACTATCAAATTCTCTAAC). To amplify the 5′ junction
and first monomer of the L1 TF donor element of interest, locus-
specific primers were designed targeting the 5′ genomic region
(fwd: GAAATTTTGTTTTTAAAAATTAAAAA) and the internal se-
quence of the L1 promoter (rev: TTCCAAAAACTATCAAATTCT
CTAAC). Fifty PCR cycles were carried out using the following con-
ditions: 95°C for 2 min, 50 cycles of 95°C for 30 sec, 54°C for 30
sec, and 72°C for 30 sec, followed by 72°C for 5 min. DMSO at a
final concentration of 0.1% was added to the PCR reactions. PCR
products were run on a 2% agarose gel, excised, purified using phe-
nol-chloroform extraction, and subjected to library preparation us-
ing theNEBNextUltra II DNALibrary PrepKit (Illumina) following
the manufacturer’s instructions. Barcoded libraries were pooled
and sequenced on an Illumina MiSeq platform using a 2 × 300-
bp paired-end reagent kit. Paired-end sequencing reads were as-
sembled into contigs via FLASH (Magoč and Salzberg 2011) using
default parameters. Contigs matching each target sequence were
identified based on the primers carried at their termini. Per sample,
50 reads were randomly selected and analyzed using QUMA
(QUantification tool for Methylation Analysis) (Kumaki et al.
2008) with default parameters, plus requiring strict CpG recogni-
tion and, in the case of the overall L1methylation, excluding iden-
tical bisulfite sequences.
Human TTC28 donor L1 methylation analysis
The methylation state of the CpG island present in the TTC28
donor L1 promoter region was analyzed with genomic DNA
extracted from patient ICC.75 tumor and nontumor liver samples.
Genomic DNA was bisulfite-converted using the EZ DNA
Methylation-GoldKit (ZymoResearch), following themanufactur-
er’s instructions with the following specifications: 500 ng gDNA
was treated per reaction, the desulfonation reactionwas conducted
for 20min at room temperature, andDNAwas eluted in 25 µL final
volume. PCR amplification was conducted using MyTaq polymer-
ase, with a locus-specific primer placed in the 5′ genomic flank
(ATTTTAGTTTGGGAGATAGAGYGA) and a reverse primer located
in the donor L1 5′ UTR (ACTATAATAAACTCCACCCAAT). PCR re-
actions were performed in 20-µL final volume reactions, using 1×
reaction buffer, 20 pmol of each primer, and 1 U of enzyme. The
following cycling conditions were used: 95°C for 2 min, then 40
cycles of 95°C for 30 sec, 54°C for 30 sec, 72°C for 30 sec, followed
by a single extension step at 72°C for 5 min. PCR amplicons were
resolved, processed for library preparation, Illumina sequenced,
and analyzed via QUMA as detailed above for the mouse methyla-
tion analysis, except here a TruSeq DNA PCR-Free Library Prepara-
tion Kit (Illumina) was used for library preparation.
qRT-PCR analysis
Snap-frozen tumor and matched nontumor liver samples from 10
patients, including HCC.58, were shaved with a scalpel on dry ice
and resuspended in TRIzol Reagent (#15596-026, Invitrogen, Life
Technologies) following the manufacturer’s instructions for total
RNA isolation. Quantification was performed using NanoDrop
1000 (Thermo Fisher Scientific). Two micrograms total RNA were
treated with DNase I (#AM1906, Ambion, Life Technologies) and
used as template for cDNA synthesis with SuperScript III Reverse
Transcriptase (#18080-093, Invitrogen, Life Technologies) follow-
ing the manufacturer’s instructions. Two micrograms total RNA
were processed as described with no reverse transcriptase added
to the cDNA synthesis reaction for use as negative control (RT−).
cDNA was diluted to final concentrations of 1:2, 1:8, 1:32, 1:128,
1:256, 1:512, and 1:1024, and used to generate a standard curve
for each primer set. Samples were diluted to 1:20 final concentra-
tion for qRT-PCR. Real time PCRs were performed using
KiCqStart SYBR Green qPCR ReadyMix Low ROX (Sigma-Aldrich)
and run on a ViiA 7 Real-Time PCR System (Life Technologies)
with standard curve experiment analysis settings with the follow-
ing PCR conditions: 20 sec at 95°C, then 40 cycles of 5 sec at 95°C
and 20 sec at 60°C, followedby aMelt Curve stage of 15 sec at 95°C,
1min at 60°C, and 15 sec at 95°C. Negative control qRT-PCRs were
performed usingwater as template (no template control, NTC) and
2 µL of RT− reaction; no amplification was detected. Both
KHDRBS2 isoforms (NM_152688) were assessed using 5′-TCTGG
TCGTGGCAGAGGTAT and 5′- TCCACGGGTTACAGTGCTTC as
forward primers and reverse primers. TATA-box binding protein
mRNA (TBP, NM_003194) was amplified using 5′-GCAAGGGT
TTCTGGTTTGCC and 5′-GGGTCAGTCCAGTGCCATAA as for-
ward primers and reverse primers. Relative expression levels of
KHDRBS2were calculated using three technical replicates and nor-
malized to TBP. Statistical analysis was performed with Prism5
(GraphPad Software), applying a two-way ANOVA followed by
Tukey’s post hoc analysis.
Ethics approval and consent to participate
Experiments involving animals were performed in accordance
with Italian laws (D.lgs. 116/92), which enforces the EU 86/609 di-
rective. Human samples were analyzed with approval from the
French Institute of Medical Research and Health (Ref: 11-047),
the East of Scotland Research Ethics Service (Ref: LR/11/ES/
0022), and the Mater Health Services Human Research Ethics
Committee (Ref: 1915A).
Data access
RC-seq, mRC-seq, and WGS data from this study have been sub-
mitted to the European Nucleotide Archive (ENA; http://www.
ebi.ac.uk/ena/) under project accession number PRJEB18756.
Sanger trace files from this study have been submitted to the
NCBI Trace Archive (http://www.ncbi.nlm.nih.gov/Traces/home/
index.cgi) with TI numbers 2344290281–2344290314.
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